Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 20.28 0.17 (0.85%) Market Cap: 1.72 Bil Enterprise Value: 1.28 Bil PE Ratio: 0 PB Ratio: 3.50 GF Score: 54/100

Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 01:15AM GMT
Release Date Price: $22.64 (-0.66%)
Anupam Rama JPMorgan Chase;Co;Analyst

&-

All right. Let's get started, and welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analyst here at JPMorgan. I'm joined by my squad, Priyanka Grover, [Le Re Hall], Malcolm Kuno. Our next presenting company is Syndax and presenting on behalf of the company, we have CEO, Michael Metzger. Michael?

Michael Metzger
Syndax Pharmaceuticals, Inc. - CEO & Director

Thank you, Anupam. Thank you, JPMorgan, for having us to this year's conference. So we a pleasure to present to you all of you today and give you an update on our progress. It's been a really very exciting year as Anupam said, I'm Michael Metzger, CEO of the company. So this is our forward-looking disclosure as others. We are making forward-looking statements today. I ask you to refer to our SEC documents for further information related to forward-looking statements.

I'll start off today talking a little bit about our two programs, actually a lot about our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot